Literature DB >> 3120353

Correlation between Branhamella catarrhalis adherence to oropharyngeal cells and seasonal incidence of lower respiratory tract infections.

N Mbaki1, N Rikitomi, T Nagatake, K Matsumoto.   

Abstract

Bacterial colonization of the oropharynx is the initial event in most lower respiratory tract infections. To study the role of bacterial adherence in lower respiratory tract infections caused by Branhamella catarrhalis (B. catarrhalis) in winter, in vitro adherence assays of the organism to human oropharyngeal cells were carried out in winter, spring, summer and autumn. A total of 57 adults of both sexes were studied from January to December 1985. Forty eight persons of 57 had chronic pulmonary diseases and the remaining 9 persons had other clinical entities and served as the control group. Predominance of lower respiratory tract infections caused by B. catarrhalis with high adherence rate was observed in winter. Adherence activity was moderate in spring and autumn and low in summer and accompanied by a similar incidence of lower respiratory tract infections with this bacteria. In addition, similar results were found in patients in whom investigations were done successively in the above four seasons. Bacterial adherence activity to cells however, was weak in winter in the control group. These results indicate that seasonal variation plays a significant role in the ability of B. catarrhalis to adhere to oropharyngeal cells. This is an important pathogenic factor correlated with the incidence of lower-respiratory tract infections in these patients.

Entities:  

Mesh:

Year:  1987        PMID: 3120353     DOI: 10.1620/tjem.153.111

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  11 in total

1.  The macrophage response to bacteria. Modulation of macrophage functional activity by peptidoglycan from Moraxella (Branhamella) catarrhalis.

Authors:  R Keller; J E Gustafson; R Keist
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

2.  Branhamella catarrhalis in lower respiratory tract secretions in adults.

Authors:  H Schønheyder; T Ejlertsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

3.  Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response.

Authors:  Violeta Spaniol; Sara Bernhard; Christoph Aebi
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

Review 4.  [Moraxella catarrhalis: virulence and resistance mechanisms].

Authors:  W Cullmann
Journal:  Med Klin (Munich)       Date:  1997-03-15

5.  Adenovirus serotype 1 does not act synergistically with Moraxella (Branhamella) catarrhalis to induce otitis media in the chinchilla.

Authors:  L O Bakaletz; D M Murwin; J M Billy
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

6.  National Scientific Medical Meeting. The Royal College of Physicians of Ireland. Dublin, 8-9 April 1994. Abstracts.

Authors: 
Journal:  Ir J Med Sci       Date:  1994-04       Impact factor: 1.568

Review 7.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

8.  Expression of the Oligopeptide Permease Operon of Moraxella catarrhalis Is Regulated by Temperature and Nutrient Availability.

Authors:  Megan M Jones; Timothy F Murphy
Journal:  Infect Immun       Date:  2015-06-22       Impact factor: 3.441

Review 9.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

10.  RNA-Seq-based analysis of the physiologic cold shock-induced changes in Moraxella catarrhalis gene expression.

Authors:  Violeta Spaniol; Stefan Wyder; Christoph Aebi
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.